Top insider buys and sells disclosed for Friday
Enovis Corp. (ENOV) insiders bought shares near a 52-week low, with CEO Damien McDonald acquiring 13,035 shares at $19.10-$19.16. Atara Biotherapeutics (ATRA) director bought 104,166 shares at $9.60. Smith-Midland Corp. (SMID) insiders also made purchases. Illumina (ILMN) director sold $57.2M in shares near a 52-week high. Caris Life Sciences (CRIS) exec sold $14.8M in shares. Okta (OKTA) CFO sold 80,000 shares. Krystal Biotech (KRY) execs sold shares near a 52-week high.
How this was made
The 30-second read
Why it matters
While some insiders bought at low levels, others sold after strong gains; overall impact is modest.
Market read
Insider activity provides limited trading cues; most moves are modest and likely already reflected in price.
What to watch
Many purchases are small relative to float; market may already price in insider sentiment.
Background
The article aggregates recent Form 4 insider transactions across several U.S. listed companies.
Ticker impact
CEO Damien McDonald bought 13,035 shares as ENOV trades near its 52‑week low.
Modest upside if buying continues.
Insider purchase at a discount may indicate confidence, but size is modest relative to market cap.
Director Brian Cherry purchased 104,166 shares while ATRA stock surged 81% over six months.
Limited impact; price already elevated.
Buy may reflect personal stake, but stock appears overvalued per analysis.
CEO Ashley Smith bought 2,000 shares as SMID trades near its 52‑week low.
Potential short‑term support.
Buy size is small; impact limited unless more purchases follow.
Director Keith Meister sold $57.2 M of ILMN shares near its 52‑week high.
Possible short‑term downside.
Large sale size relative to holdings may signal concerns.
President David Baxley Spetzler sold $14.8 M of CRIS shares while the stock trades at $25.07.
Limited effect; market already pricing in performance.
Sell size modest; broader market sentiment dominates.
CFO Brett Tighe sold 80,000 OKTA shares under a 10b5‑1 plan near its 52‑week high.
Potential short‑term pullback.
Sizeable sale but planned; may not reflect new information.
President/CEO Krish Krishnan sold 25,900 KRYS shares after a 139% gain year‑to‑date.
Minor short‑term pressure.
Sell aligns with typical profit‑taking after large rally.
Market effects
Healthcare and tech insiders' activity may influence sector sentiment.
U.S. market focus; no broader regional effect.
Limited to U.S. listed companies.
Counterpoint
Insider sells may be routine profit‑taking, not a bearish signal.
Key entities
- companyEnovis Corp.
Medical device maker with recent insider purchases.
- companyIllumina
Genomics firm with a large insider sell.
